D121 is a NCE that has a very good potential to treat leishmaniasis, a neglected tropical disease.
We are at the end of phase I. With a very good international team we can take the development further through phase II and III clinical trials. Upon approval of NDA, this molecule is eligible for a Priority Review Voucher.
Interested in receiving an investment proposal for this project? Please fill in the form.